Skip to content
1st Counsel – Lifestyle
Author:
Precigen, Inc
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
June 15, 2026
Precigen Reports ‘Robust Uptake’ of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
April 7, 2026